Claude B. Sirlin

Hepatology · 2002–2019

A researcher in the Science corpus: 9 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Claude B. Sirlin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jordi Bruix1 , 2
  2. J. Llovet
  3. R. Salem

Papers from Claude B. Sirlin's perspective

Ordered by how strongly the researchers Claude B. Sirlin trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  2. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
  4. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
  5. Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (Annals of Surgery)
  6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  7. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
  8. Management of hepatocellular carcinoma: An update (Hepatology)
  9. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (Gastroenterology)
  10. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria (Annals of Surgery)

Their papers